14346621 < 1435-1463 < 1435-4373

Facettes :

List of bibliographic references

Number of relevant bibliographic references: 82.
[0-50] [0 - 20][0 - 50][50-70]

Ident.	Authors (with country if any)	Title
000056 (1983)	W. Danielczyk	Various mental behavioral disorders in Parkinson's disease, primary degenerative senile dementia, and multiple infarction dementia
000075 (1981)	J. Marttila ; K. Rinne	Epidemiology of Parkinson's disease—An overview
000084 (1986)	G. Ransmayr ; W. Poewe ; S. Plörer ; F. Gerstenbrand ; K. Leidlmair ; U. Mayr	Prognostic implications of the motor symptoms of Parkinson's disease with respect to clinical, computertomographic and psychometric parameters
000129 (1996)	M. Rodríguez ; M. Sabaté ; E. Troncoso	Time and frequency domain analysis for the assessment of heart autonomie control in Parkinson's disease
000170 (1993)	E. Fertl ; E. Auff ; A. Doppelbauer ; F. Waldhauser	Circadian secretion pattern of melatonin in de novo Parkinsonian patients: evidence for phase-shifting properties of l-dopa
000204 (1993)	H. Baas ; K. Stecker ; A. Fischer	Value and appropriate use of rating scales and apparative measurements in quantification of disability in Parkinson's disease
000208 (1993)	G. Arnold ; B. Bondy ; O. Bandmann ; Th. Gasser ; J. Schwarz ; C. Trenkwalder ; M. Wagner ; W. Poewe ; H. Oertel	3H-spiperone binding to lymphocytes fails in the differential diagnosis of de novo Parkinson syndromes
000279 (1996)	M. Gerlach ; W. Kuhn ; Th. Müller ; P. Klotz ; H. Przuntek	Sustained-release of levodopa: single dose study of a new formulation
000408 (1994)	P. Vieregge	Genetic factors in the etiology of idiopathic Parkinson's disease
000461 (1981)	K. Rinne	Treatment of Parkinson's disease: Problems with a progressing disease
000507 (1990)	K. Perry ; J. Smith ; A. Court ; H. Perry	Cholinergic nicotinic and muscarinic receptors in dementia of Alzheimer, Parkinson and Lewy body types
000512 (1992)	M. Pinter ; J. Helscher ; J. Nasel ; E. Riedl ; G. Schnaberth	Quantification of motor deficit in Parkinson's disease with a motor performance test series
000551 (1990)	H. Braak ; E. Braak	Cognitive impairment in Parkinson's disease: amyloid plaques, neurofibrillary tangles, and neuropil threads in the cerebral cortex
000687 (1979)	W. Wesemann ; G. Dette-Wildenhahn ; H. Fellehner	In vitro studies on the possible effects of 1-aminoadamantanes on the serotonergic system in M. Parkinson
000701 (1990)	K. Jellinger ; W. Paulus ; I. Grundke-Iqbal ; P. Riederer ; H. Youdim	Brain iron and ferritin in Parkinson's and Alzheimer's diseases
000770 (1995)	G. Ransmayr ; G. Künig ; M. Neubauer ; M. Wagner ; M. Falk	Effect of age and disease duration on parkinsonian motor scores under levodopa therapy
000791 (1995)	A. Loeffler ; A. Lewitt ; J. Demaggio ; L. Juneau ; E. Milbury ; R. Matson	Markers of dopamine depletion and compensatory response in striatum and cerebrospinal fluid
000804 (1976)	P. Riederer ; St. Wuketich	Time course of nigrostriatal degeneration in parkinson's disease
000816 (1994)	C. Mytilineou ; P. Werner ; S. Molinari ; A. Di Rocco ; G. Cohen ; D. Yahr	Impaired oxidative decarboxylation of pyruvate in fibroblasts from patients with Parkinson's disease
000817 (1990)	G. Ransmayr ; W. Bitschnau ; B. Schmidhuber-Eiler ; W. Berger ; E. Karamat ; W. Poewe ; W. Kemmler	Slowing of high-speed memory scanning in Parkinson's disease is related to the severity of parkinsonian motor symptoms
000852 (1972)	W. Birkmayer ; W. Danielczyk ; E. Neumayer ; P. Riederer	The balance of biogenic amines as condition for normal behaviour
000910 (1995)	-M. Wu ; L. Murphy ; C. Chiueh	Neuronal protective and rescue effects of deprenyl against MPP+ dopaminergic toxicity
000946 (1993)	S. Markus ; M. Tomkins ; M. Stern	Increased prevalence of undernutrition in Parkinson's disease and its relationship to clinical disease parameters
000980 (1994)	S. Enochs ; T. Sarna ; L. Zecca ; A. Riley ; M. Swartz	The roles of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: A hypothesis
000A26 (1993)	M. Pinter ; J. Helscher	Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease
000A27 (1985)	W. Birkmayer ; J. Knoll ; P. Riederer ; H. Youdim ; Vera Hars ; J. Marton	Increased life expectancy resulting from addition of l-deprenyl to Madopar® treatment in Parkinson's disease: A longterm study
000A61 (1993)	E. Fertl ; A. Doppelbauer ; E. Auff	Physical activity and sports in patients suffering from Parkinson's disease in comparison with healthy seniors
000B96 (1996)	H. Przuntek ; D. Welzel ; M. Gerlach ; E. Blümner ; W. Danielczyk ; -J. Kaiser ; H. Kraus ; H. Letzel ; P. Riederer ; K. Überla	Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study
000C56 (1995)	G. Finali ; M. Piccirilli ; S. Rizzuto	Neuropsychological characteristics of parkinsonian patients with lateralized motor impairment
000C61 (1996)	H. Braak ; E. Braak ; D. Yilmazer ; I. De Vos ; H. Jansen ; J. Bohl	Pattern of brain destruction in Parkinson's and Alzheimer's diseases
000D82 (1982)	-Ch. Curtius ; H. Müldner ; A. Niederwieser	Tetrahydrobiopterin: Efficacy in endogenous depression and Parkinson's disease
000D95 (1981)	K. Rinne ; P. Lönnberg ; V. Koskinen	Dopamine receptors in the parkinsonian brain
000E32 (1996)	M. Gerlach ; P. Riederer	Animal models of Parkinson's disease: An empirical comparison with the phenomenology of the disease in man
000E44 (1992)	J. Málly	Some new aspects of the effect of (−)deprenyl in Parkinson's disease—a retrospective study
001014 (1993)	J. Kornhuber ; M. Weller ; P. Riederer	Glutamate receptor antagonists for neuroleptic malignant syndrome and akitetic hyperthermic Parkinsonian crisis
001162 (1991)	E. Fertl ; E. Auff ; A. Doppelbauer ; F. Waldhauser	Circadian secretion pattern of melatonin in Parkinson's disease
001335 (1993)	H. Heinonen ; M. Savij Rvi ; M. Kotila ; A. Hajba ; M. Scheinin	Effects of monoamine oxidase inhibition by selegiline on concentrations of noradrenaline and monoamine metabolites in CSF of patients with Alzheimer's disease
001463 (1989)	M. Melzacka ; F. Block ; W. Weseman ; G. Sturm ; -H. Sontag	Effects of two isomeric 1-aminoadamantanes on the membrane anisotropy and on alpha- and gamma-motoneurones excitability
001470 (1992)	H. Soininen ; -L. Helkala ; V. Laulumaa ; R. Soikkeli ; P. Hartikainen ; J. Riekkinen	Cognitive profile of Alzheimer patients with extrapyramidal signs: A longitudinal study
001479 (1995)	A. Espino ; M. Calopa ; S. Ambrosio ; J. Ortolà ; J. Peres ; A. Navarro	CSF somatostatin increase in patients with early parkinsonian syndrome
001523 (1996)	W. Kuhn ; Th. Müller ; M. Gerlach ; E. Sofic ; G. Fuchs ; N. Heye ; R. Prautsch ; H. Przuntek	Depression in Parkinson's disease: biogenic amines in CSF of “de novo” patients
001562 (1989)	H. Lee ; M. Mendoza ; T. Dvorozniak ; E. Chung ; H. Van Woert ; D. Yahr	Platelet monoamine oxidase in Parkinson patients: effect of L-deprenyl therapy
001629 (1964)	W. Umbach ; W. Fünfgeld	Klinische Untersuchungen der vegetativen Steuerung beim Parkinson-Syndrom postencephalitischer und anderer Ätiologie vor und nach der stereotaktischen Operation
001655 (1995)	I. Bodis-Wollner ; C. Borod ; B. Cicero ; S. Haywood ; S. Raskin ; L. Mylin ; M. Sliwinski ; A. Falk ; D. Yahr	Modality dependent changes in event-related potentials correlate with specific cognitive functions in nondemented patients with Parkinson's disease
001686 (1993)	M. Palmer ; T. Dekosky	Monoamine neurons in aging and Alzheimer's disease
001762 (1993)	T. Klockgether ; P. Jacobsen ; -A. Löschmann ; L. Turski	The antiparkinsonian agent budipine is an N-methyl-D-aspartate antagonist
001791 (1978)	D. Yahr	Overview of present day treatment of Parkinson's disease
001836 (1993)	J. Helscher ; M. Pinter	Speed and power of higher cerebral functions in parkinsonian patients
001870 (1990)	P. Fischer ; G. Gatterer ; M. Simanyi ; K. Jellinger ; A. Marterer ; K. Danielczyk ; W. Danielczyk	Memory deficits in advanced Parkinson's disease
001977 (1991)	D. Prell ; K. Khandelwal ; S. Burns ; P. Blandina ; M. Morrishow ; P. Green	Levels of pros -methylimidazoleacetic acid: Correlation with severity of Parkinson's disease in CSF of patients and with the depletion of striatal dopamine and its metabolites in MPTP-treated mice
001A24 (1996)	W. Oder ; T. Brücke ; H. Kollegger ; J. Spatt ; S. Asenbaum ; L. Deecke	Dopamine D2 receptor binding is reduced in Wilson's disease: Correlation of neurological deficits with striatal123I-Iodobenzamide binding

---

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Corpus

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/ISSN.i -k "1435-1463" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/ISSN.i  \
                -Sk "1435-1463" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonV1
   |flux=    Main
   |étape=   Corpus
   |type=    indexItem
   |index=    ISSN.i
   |clé=    1435-1463
}}

---

This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 18:06:51 2016. Site generation: Wed Mar 6 18:46:03 2024